MedPath

Manganese

Generic Name
Manganese
Brand Names
Concept Ob, Multitrace-4, Multitrace-5, Multrys, Tandem Plus
Drug Type
Small Molecule
Chemical Formula
Mn
CAS Number
7439-96-5
Unique Ingredient Identifier
H6EP7W5457
Background

Manganese is a transition metal with a molar mass of 54.94g/mol. Manganese is considered critical for human health, and plays important roles in development, metabolism, and the antioxidant system. That said, excessive manganese intake is associated with manganism, a neurodegenerative disorder that causes dopaminergic neuronal death and parkinsonian-like symptoms.

Indication

Indicated for use as a supplement to intravenous solutions given for Total Parenteral Nutrition (TPN). Administration helps to maintain plasma levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.

Associated Therapies
Mineral supplementation therapy, Total parenteral nutrition therapy, Vitamin supplementation, Dietary supplementation

An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma

Phase 1
Conditions
Lymphoma
Solid Tumor
Interventions
Radiation: Radiotherapy
Drug: Chemo-immunotherapy
First Posted Date
2021-05-05
Last Posted Date
2021-05-05
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
10
Registration Number
NCT04873440
Locations
🇨🇳

Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China

A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC

Phase 1
Conditions
Biliary Tract Cancer (BTC)
Interventions
First Posted Date
2019-07-01
Last Posted Date
2019-07-09
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
20
Registration Number
NCT04004234
Locations
🇨🇳

Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China

A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas

Phase 1
Conditions
Solid Tumor
Lymphoma
Interventions
Drug: Anti-PD-1 antibody
Combination Product: Systemic therapy
First Posted Date
2019-06-19
Last Posted Date
2019-08-28
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
20
Registration Number
NCT03991559
Locations
🇨🇳

Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer

Phase 1
Conditions
Pancreatic Cancer
Interventions
First Posted Date
2019-06-18
Last Posted Date
2020-12-23
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
50
Registration Number
NCT03989310
Locations
🇨🇳

Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China

A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer

First Posted Date
2019-06-18
Last Posted Date
2024-07-15
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
84
Registration Number
NCT03989336
Locations
🇨🇳

Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath